COMPARISON BETWEEN GENERIC DRUGS AND BRAND NAME DRUGS FROM BIOEQUIVALENCE AND THERMOEQUIVALENCE PROSPECTIVE
DOI:
https://doi.org/10.22159/ijpps.2017v9i6.18735Keywords:
Generic drug, Brand name drug, Thermoequivalence, Bioequivalence, Active materials, Inactive materialsAbstract
The belief that generic drugs are inferior to brand name drugs has been always under debate. Especially since the price of generic drugs is generally far cheaper than brand-name drugs. Although, this is because of waiving the preclinical studies and clinical trials for the generic drug, the quality, and purity of materials used for generic drug preparation is still arguable. Thus, the objective of this overview was to find out the tolerable deviations between generic and brand name drugs which should not alter the pharmacology. Using inactive additives in the generic drug different than in the brand name drug, such as binders, glidants, diluents, anti-adherents, disintegrants or polymer carrier material and filler should not change the drug bioavailability and pharmacokinetic parameters as long as both products using the identical active ingredient(s) in equivalent amounts. Even if both drug products are bioequivalent to each other in terms of active ingredient, they are not in terms of inactive ingredients. Hence, the probability of unexpected adverse drug reaction and allergies from the generic formulation are possible, especially, when people react sensitive toward specific component. Therefore, the occasional negative response occurring upon the switch from brand-name drug to the generic drug can be attributed to intra-and inter-patient variations toward inactive ingredients. Variations toward inactive ingredients can be obtained experimentally by utilizing a proper thermoanalytical technique. As a result, thermoequivalence of generic drugs to brand name drugs can be determined based on thermal information obtained from both products. In conclusion, thermoequivalence study can be a useful tool to demonstrate any possible variation between the inactive ingredients of both products.
Downloads
References
Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 y of bioequivalence data from the United States food and drug administration. Ann Pharmacother 2009; 43:1583-97.
Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997;277:1205-13.
Arafat M. Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review. Int J Pharm Pharm Sci 2015;7:16-21.
Khatavkar UN, Kumar KJ, Shimpi SL. Novel approaches for the development of oral controlled release compositions of galantamine hydrobromide and paroxetine hydrochloride hemihydrate: a review. Int J Appl Pharm 2016;8:1-6.
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy 2011;31:386-93.
Dicken JE. Drug pricing: research on savings from generic drug Use. GAO US Government Accountability Office; 2011;1-19. Available from: http://www.gao.gov/products/GAO-12-371R. [Last accessed on 20 Feb 2017]
FDA Fact sheet: What’s involved in reviewing and approving generic drugs applications? Available from: https:// www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm506040. htm [Last accessed on 20 Feb 2017]
Moore N, Berdaï D, Bégaud B. Are generic drugs really inferior medicines? Clin Pharmacol Ther 2010;88:302-4.
Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-8.
McCormack J, Chmelicek JT. Generic versus brand name: the other drug war. Can Fam Physician 2014;60:911.
Stegemann S, Klebovich I, Antal I, Blume HH, Magyar K, Németh G, et al. Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. Eur J Pharm Sci 2011;44:447-54.
Nadler HL, Degraft-Johnson D. Demystifying FDA’s 505(b), drug registration process. Regulatory Focus; 2009. p. 25-30.
Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol 2013;14:2-19.
Arafat M, Golocorbin KS, Mikov M. The measurement of cefotaxime sodium in rat plasma after oral administration: a sensitive HPLC-UV method. Int J Pharm Pharm Sci 2015;7:343-46.
Arafat M. Simple HPLC validated method for determination of diltiazem hydrochloride in Human. Int J Pharm Pharm Sci 2014;6:213-16.
Arafat M, Zahaa A, Mikov M. Determination of nifedipine in rat plasma using HPLC-UV detector: a simple method for pharmacokinetics and oral bioavailability studies. Int J Pharm Pharm Sci 2016;8:98-102.
Arafat M. The effect of intestinal bile on the stability of lipid-based vesicular system used as oral drug carriers. Global Blood Therapeutics 2016;2:1-2.
Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med 2014;161:96-103.
Thakkar KB, Billa G. The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs. Front Pharmacol 2013;4:113.
WHO. Guidance on INN. Essential medicines and health products; 2013a. Available from: www.who.int/medicines/ services/inn/innguidance/en/index. html. [Last accessed on 20 Feb 2017]
Mukti AA, Jannah F, Nurrochmad A, Lukitaningsih E. Development and validation method for quantitative determination of ciprofloxacin in human plasma and its application in bioequivalence test. Asian J Pharm Clin Res 2016;9:89-95.
Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health 2012;15:664-73.
Arafat M, Kirchhoefer C, Mikov M. Mixed micelles loaded with bile salt: an approach to enhance intestinal transport of the BCS class III drug cefotaxime in rats. Eur J Drug Metab Pharmacokinet; 2016. p. 1-11.
Golocorbin-Kon S, Mikov M, Arafat M, Lepojevic Z, Mikov I, Sahman-Zaimovic M, et al. Cefotaxime pharmacokinetics after oral application in the form of 3α, 7α-dihydroxy-12-keto-5β-cholanate microvesicles in rat. Eur J Drug Metab Pharmacokinet 2009;34:31-6.
Arafat M. Bilosomes as a drug delivery system, University of Otago; 2012. Available from: http://hdl.handle.net/ 10523/2157. [Last accessed on 20 Feb 2017].
Mayer T, May TW, Altenmuller DM, Sanmann M, Wolf P. Clinical problems with generic antiepileptic drugs. Clin Drug Invest 1999;18:17-26.
Miraci M, Haloci E, Toto B. The evaluation of the rational use of some drugs in albania. Asian J Pharm Clin Res 2015;8:90-4.
Mumoli N, Cei M, Luschi R, Carmignani G, Camaiti A. Allergic reaction to croscarmellose sodium used as excipient of a generic drug. Q J Med 2011;104:709-10.
Gallelli L, Palleria C, De Vuono A, Mumoli L, Vasapollo P, Piro B, Russo E. Safety and efficacy of generic drugs with respect to brand formulation. J Pharmacol Pharmacother 2013;4:S110–4.
Shields BJ, Nahata MC. Efficacy of brand-name vs. generic fluoxetine. Perspect Psychiatr Care 2003;39:122-4.
Arafat M, Salam A, Arafat†O. The association of type 2 diabetes with obesity and other factors: in the multinational community. Int J Pharm Pharm Sci 2014;6:257-60â€.
Blier P. Brand versus generic medications: the money, the patient and the research. J Psychiatry Neurosci 2003;28:167-8.
Attia AK, Ibrahim MM, El-Ries MA. Thermal analysis of some antidiabetic pharmaceutical compounds. Adv Pharm Bull 2013;3:419-24.
Attia AK, Abdel-Moety MM. Thermoanalytical investigation of terazosin hydrochloride. Adv Pharm Bull 2013;3:147-52.
Saber RA, Attia AK, Salem WM. Thermal analysis study of antihypertensive drugs telmisartan and cilazapril. Adv Pharm Bull 2014;4:283-7.
Singh S, Wu C, Williams PT. Pyrolysis of waste materials using TGA-MS and TGA-FTIR as complementary characterisation techniques. J Anal Appl Pyrolysis 2012;94:99-107.
Wendlandt WW, George TD. The thermal decomposition of metal complexes—I: Thermogravimetric and differential thermal analysis. J Inorg Nucl Chem 1961;21:69-76.
Dordunoo SK, Ford JL, Rubinstine MH. Solidification studies of polyethylene glycols, gelucire 44/14 or their dispersions with triamterene or temazepam. J Pharm Pharmacol 1996;48:782-9.
Oliveira GGG, Ferraz HG, Matos JSR. Thermoanalytical study of glibenclamide and excipients. J Therm Anal Calorim 2005;79:267-70.
Gutch PK, Jitendra S, Alankar S, Anurekha J, Ganesan K. Thermal analysis of the interaction between 2-PAM chloride and various excipients in some binary mixtures by TGA and DSC. J Therm Anal Calorim 2013;111:1953-8.
Published
How to Cite
Issue
Section
